Inside the 8-week study.
Alongside the published research on its ingredients, ProleevaMax has been through one in-house human evaluation. Here is exactly what it measured — and what it didn’t.
8-week human evaluation
point reduction in pain-intensity score on the McGill Pain Questionnaire (MPQ) at week 8.†
p = 0.042 · statistically significant
What “significant” means here
A result is called statistically significant when its p-value falls below 0.05. This evaluation came in at p = 0.042 — just under the line.
The evaluation also noted favorable shifts in select inflammatory biomarkers. Specific markers and values were not reported.
The protocol
How the 90 days were structured.
Four capsules daily. The week-8 milestone is where the evaluation took its measurement.
- Week 21
Begin & Absorb
Active ingredients enter circulation. Piperine supports bioavailability.
- Week 42
Early Ease
Steadier mornings, more comfortable movement, clearing brain fog.
- Week 83
Measured Change
A statistically significant improvement in McGill Pain Questionnaire scores (p = 0.042): a 22-point reduction in pain intensity.†
- Day 904
The Pause Test
Complete the protocol. Consider pausing to confirm results.
† Results from an 8-week human evaluation. Individual results may vary. This was a single 8-week human evaluation, not a large-scale, peer-reviewed clinical trial. A result of p = 0.042 is statistically significant but modest, and larger research is still developing. ProleevaMax is not “clinically proven” to treat any condition.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.